Combretastatin A-4 analogs: Past, present, and future directions
Mustafa, M., A. Mostafa, Y., E. Abd Elbaky, A., Mohamed, M., Abdelhamid, D., M. N. Abdelhafez, E., Aly, O. (2022). Combretastatin A-4 analogs: Past, present, and future directions. EKB Journal Management System, 1(1), 55-64. doi: 10.21608/odr.2022.156180.1008
Muhamad Mustafa; Yaser A. Mostafa; Atef E. Abd Elbaky; Mahmoud Mohamed; Dalia Abdelhamid; ElShimaa M. N. Abdelhafez; Omar M. Aly. "Combretastatin A-4 analogs: Past, present, and future directions". EKB Journal Management System, 1, 1, 2022, 55-64. doi: 10.21608/odr.2022.156180.1008
Mustafa, M., A. Mostafa, Y., E. Abd Elbaky, A., Mohamed, M., Abdelhamid, D., M. N. Abdelhafez, E., Aly, O. (2022). 'Combretastatin A-4 analogs: Past, present, and future directions', EKB Journal Management System, 1(1), pp. 55-64. doi: 10.21608/odr.2022.156180.1008
Mustafa, M., A. Mostafa, Y., E. Abd Elbaky, A., Mohamed, M., Abdelhamid, D., M. N. Abdelhafez, E., Aly, O. Combretastatin A-4 analogs: Past, present, and future directions. EKB Journal Management System, 2022; 1(1): 55-64. doi: 10.21608/odr.2022.156180.1008

Combretastatin A-4 analogs: Past, present, and future directions

Octahedron Drug Research
Article 6, Volume 1, Issue 1, September 2022, Page 55-64  XML PDF (829.32 K)
Document Type: Review Articles
DOI: 10.21608/odr.2022.156180.1008
View on SCiNiTO View on SCiNiTO
Authors
Muhamad Mustafa email orcid 1; Yaser A. Mostafa2; Atef E. Abd Elbaky3; Mahmoud Mohamed4; Dalia Abdelhamid5; ElShimaa M. N. Abdelhafez5; Omar M. Alyorcid 6
1IBMM, Univ. Montpellier, CNRS, ENSCM, Montpellier, France
2Pharmaceutical Organic Chemistry Department, Faculty of Pharmacy, Assiut University, Assiut 71526, Egypt
3Biochemistry Department, Faculty of Pharmacy, Port Said University
4Pharmacognosy Department, College of Clinical Pharmacy, Albaha University, Saudi Arabia
5Medicinal Chemistry Department, Faculty of Pharmacy, Minia University, Minia, Egypt
6Department of Medicinal Chemistry, Faculty of Pharmacy, Port Said University
Abstract
Microtubules are protein biopolymers created by polymerizing heterodimers of α and β-tubulins. Microtubule disruption induces G2/M cell cycle arrest and abnormal mitotic spindle formation. Microtubules are vital for cell division; without them, cell division cannot occur. Chemotherapeutic interference with tubulin/microtubule polymerization dynamics . Their significance in cell division makes microtubules an appealing target for anticancer drug discovery. Several naturally occurring compounds, such as vinblastine, paclitaxel, combretastatin, and colchicine exert their activity by changing tubulin dynamics, such as polymerization and depolymerization. Tubulin, an essential tumor therapy target, is one of the hotspots in the area of antineoplastic drugs, and it is of a significance importance to design novel inhibitors for this target. Both natural and synthetic scaffolds are the main tubulin inhibitors sources. In this article, the main structural features and motifs tubulin polymerization inhibitors are reviewed. Thus, it provides a theoretical basis for target optimization of new inhibitors of tubulin polymerization.
Keywords
Tubulin polymerization inhibitors; Combretastatin A-4; Anticancer agents; heterocyclic compounds
Statistics
Article View: 224
PDF Download: 239